High GD2 expression defines breast cancer cells with enhanced invasiveness
High GD2 expression defines breast cancer cells with enhanced invasiveness
复制标题
DOI：
10.1016/j.yexmp.2019.05.001
复制
发表时间：
2019-08-01
影响因子：
3.6
通讯作者：
Madjd, Zahra
中科院分区：
文献类型：
--
作者：
Mansoori, Maryam;Roudi, Raheleh;Madjd, Zahra
乳腺癌是女性中最常见的癌症。肿瘤干细胞（Cancer stem cells, CSCs）被认为与肿瘤的发生、发展、转移、复发和耐药有关。本研究旨在评价新近提出的CSC标志物GD2与另外两种传统的CSC标志物CD44和CD24在乳腺癌患者中的临床意义。材料和方法：采用组织芯片技术对168例原发性乳腺癌组织中GD2、CD44和CD24的表达进行评估。然后，评估这些标志物的表达水平与患者临床病理特征的相关性。结果：GD2高表达主要见于组织学分级高（p = 0.02）、淋巴结浸润高（p = 0.04）、肿瘤体积大（p = 0.04）、年龄大（p = 0.04）的患者。组织学分级较高的乳腺癌标本CD44 （p = 0.03）和CD24 （p = 0.05）表达也较高。CD24表达增加与淋巴结受累有显著正相关（p = 0.01）。此外，gd2 -高/ cd44 -高/ cd24 -低表型常见于淋巴结累及阳性的乳腺癌样本（p = 0.05）。结论：总之，GD2表达的增加可能决定了乳腺癌中更具侵袭性的肿瘤行为。GD2可以作为乳腺癌的诊断和预后指标。
Introduction: Breast cancer is the most frequently diagnosed cancer among women. Cancer stem cells (CSCs) are suggested to be responsible for tumor initiation, progression, metastasis, recurrence and drug resistance. This study was conducted to evaluate the clinical significance of GD2, a newly suggested CSC marker and two other traditional CSC markers, CD44 and CD24 in breast cancer patients.Material and methods: A total of 168 primary breast cancer tissues were evaluated in terms of GD2, CD44 and CD24 expression using tissue microarray. Then, the correlation of expression levels of these markers with patients' clinicopathological characteristics was assessed.Results: Higher GD2 expression was mainly found in patients with advanced histological grade (p = 0.02), presence of lymph node invasion (p = 0.04), larger size of tumors (p = 0.04) and older age (p = 0,04). Breast cancer samples with advanced histological grade also showed higher CD44 (p = 0.03) and CD24 expression (p = 0.05). A significant positive association was found between increased CD24 expression and lymph node involvement (p = 0.01). Furthermore, GD2-high/CD44-high/CD24-low phenotype was frequently seen in breast cancer samples with positive lymph node involvement (p = 0.05).Conclusion: In summary, increased expression of GD2 may define more aggressive tumor behavior in breast cancer. GD2 can well be considered as a diagnostic and prognostic marker in breast cancer.